Carbon-Coated Iron Oxide Nanoparticles Promote Reductive Stress-Mediated Cytotoxic Autophagy in Drug-Induced Senescent Breast Cancer Cells
Anna Lewińska, Adrian Radoń, Kacper Gil, Dominika Błoniarz, Agnieszka Ciuraszkiewicz, Jerzy Kubacki, Mariola Kądziołka-Gaweł, Dariusz Łukowiec, P. Gębara, Agnieszka Krogul-Sobczak, Piotr Piotrowski, Oktawia Fijałkowska, Sylwia Wybraniec, Tomasz Szmatoła, Aleksandra Kolano-Burian, Maciej Wnuk
Abstract
High Resolution Image Download MS PowerPoint Slide The surface modification of magnetite nanoparticles (Fe 3 O 4 NPs) is a promising approach to obtaining biocompatible and multifunctional nanoplatforms with numerous applications in biomedicine, for example, to fight cancer. However, little is known about the effects of Fe 3 O 4 NP-associated reductive stress against cancer cells, especially against chemotherapy-induced drug-resistant senescent cancer cells. In the present study, Fe 3 O 4 NPs in situ coated by dextran (Fe 3 O 4 @Dex) and glucosamine-based amorphous carbon coating (Fe 3 O 4 @aC) with potent reductive activity were characterized and tested against drug-induced senescent breast cancer cells (Hs 578T, BT-20, MDA-MB-468, and MDA-MB-175-VII cells). Fe 3 O 4 @aC caused a decrease in reactive oxygen species (ROS) production and an increase in the levels of antioxidant proteins FOXO3a, SOD1, and GPX4 that was accompanied by elevated levels of cell cycle inhibitors (p21, p27, and p57), proinflammatory (NFκB, IL-6, and IL-8) and autophagic (BECN1, LC3B) markers, nucleolar stress, and subsequent apoptotic cell death in etoposide-stimulated senescent breast cancer cells. Fe 3 O 4 @aC also promoted reductive stress-mediated cytotoxicity in nonsenescent breast cancer cells. We postulate that Fe 3 O 4 NPs, in addition to their well-established hyperthermia and oxidative stress-mediated anticancer effects, can also be considered, if modified using amorphous carbon coating with reductive activity, as stimulators of reductive stress and cytotoxic effects in both senescent and nonsenescent breast cancer cells with different gene mutation statuses.